In one paragraphArticle in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
19 authors.
Justine Y BruceDepartment of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.ORCID 0000-0002-5902-7430 Tiffany A GlazerDepartment of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.ORCID 0000-0002-4223-9381 Liliana L BerubeDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.ORCID 0000-0002-6673-2525 Colin A LonghurstDepartment of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.ORCID 0000-0002-2548-9610 Menggang YuUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.ORCID 0000-0002-7904-3155 Rong HuUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.ORCID 0000-0002-1502-9848 Aaron M WielandDepartment of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.ORCID 0000-0001-5798-3341 Paul M HarariUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.ORCID 0000-0002-6207-5505 Gregory K HartigDepartment of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.ORCID 0000-0002-0302-7319 Mari IidaDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.ORCID 0000-0001-7168-8680 Michael J PoellmannDivision of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin, Madison, Wisconsin.ORCID 0000-0002-0085-3957 Jiyoon BuDivision of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin, Madison, Wisconsin.ORCID 0000-0002-0153-5109 Kwangok P NickelDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.ORCID 0000-0003-0263-128X Seungpyo HongUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.ORCID 0000-0001-9870-031X Deric L WheelerUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.ORCID 0000-0001-5915-3675 Randall J KimpleUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.ORCID 0000-0001-8336-8000 Funding
UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6MUniversity of Wisconsin Institute for Clinical and Translational ResearchUL1TR002373 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI ELIZABETH S BURNSIDE, Allan R. Brasier · 2017 to 2026
$75.9MProject 4: Role of Receptor Tyrosine Kinase AXL in HNSCC Therapy ResistanceP50DE026787 · NIDCR · UNIVERSITY OF WISCONSIN-MADISON · PI HARARI, PAUL M · 2016 to 2020
$10.8MImproving the translational value of head and neck cancer patient-in-mouse modelsR37CA255330 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Randall J. Kimple · 2021 to 2026
$3.5MCooperation of the TAM and Abl family kinases in therapeutic resistance in HNCR01CA262292 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Ravi Salgia, DERIC L WHEELER · 2022 to 2026
$2.9MIntegration of EGFR Inhibitors with Radiochemotherapy in Head and Neck CancerR01CA131290 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI NYATI, MUKESH K. · 2009 to 2013
$1.5MNational Cancer Institute (NCI) P30 CA014520National Cancer Institute (NCI) R01 CA131290National Cancer Institute (NCI) R01 CA262292National Cancer Institute (NCI) R37 CA255330National Center for Advancing Translational Sciences (NCATS) UL1 TR002373National Institute of Dental and Craniofacial Research (NIDR) P50 DE026787NCATS NIH HHS UL1 TR002373NCI NIH HHS P30 CA014520NCI NIH HHS R01 CA131290NCI NIH HHS R01 CA262292NCI NIH HHS R37 CA255330NIDCR NIH HHS P50 DE026787Wisconsin Economic Development Corporation (WEDC)
6 · The paper itselfAbstract
purposeAXL is a receptor tyrosine kinase implicated in epidermal growth factor receptor resistance. The primary objective of this study was to test the hypothesis, generated in preclinical studies, that low AXL correlates with clinical response to cetuximab in patients with head and neck cancer (HNC). The secondary objectives were to further describe the feasibility and safety of preoperative administration of cetuximab. PATIENTS AND
methodsWe performed a single-site, single-arm, open-label, window-of-opportunity study utilizing preoperative cetuximab in 15 patients with HNC. Patients received two doses of cetuximab and underwent resection of their tumors. Biopsies were used to assess AXL expression and changes in Ki67 staining and to establish patient-derived xenografts (PDX). Single-cell RNA sequencing (scRNA-seq) of treated xenograft tissue was used to assess differences between sensitive and resistant tumors.
resultsFifteen subjects were registered for treatment in the study, and fourteen completed treatment with cetuximab prior to surgical resection. No correlation between AXL expression at baseline and change in tumor size in response to cetuximab was observed. Preoperative cetuximab did not delay surgical resection, and no unexpected treatment-related adverse events were reported. scRNA-seq identified that cetuximab sensitivity is marked by transcriptional remodeling, whereas resistance is associated with stable human epidermal growth factor receptor signaling and elevated Tyro, AXL, and MerTK (TAM) activity.
conclusionsDelivery of preoperative cetuximab is safe, and a short course can be utilized to identify patients with HNC responding to single-agent cetuximab treatment. SIGNIFICANCE: Preoperative cetuximab is safe and feasible in HNC, identifying early responders without delaying surgery. Although AXL was not validated as a resistance biomarker-possibly due to COVID-19-related early closure-concordance among patient outcomes, circulating tumor cells, and PDXs strongly supports this translational pipeline for future studies.
Indexed as
Antineoplastic Agents, ImmunologicalCetuximabHead and Neck NeoplasmsAdultAgedAnimalsAxl Receptor Tyrosine KinaseDrug Resistance, NeoplasmFemaleHumansMaleMiceMiddle AgedNeoadjuvant TherapyPreoperative CareProto-Oncogene ProteinsAntineoplastic Agents, ImmunologicalAXL protein, humanAxl Receptor Tyrosine KinaseCetuximabProto-Oncogene ProteinsReceptor Protein-Tyrosine Kinases
Identifiers
PMID42691952
PMCPMC13639994
What Socratic holds
Textmetadata
Read underepoch 390